DuPont to Sell Aramids Business to Arclin

DuPont has recently announced an agreement to divest its Aramids business to Arclin, with the transaction valued at around $1.8 billion. The deal includes the transfer of assets like Kevlar® and Nomex® to Arclin, ensuring DuPont to receive pre-tax cash proceeds of approximately $1.2 billion, with an additional note receivable of $300 million. Furthermore, DuPont will secure a non-controlling common equity interest in the new Arclin company, estimated at $325 million, representing a stake of about 17.5% at the time of closure.

Lori Koch, the CEO of DuPont, expressed enthusiasm, stating that the divestiture of the Aramids business is a strategic move to enhance the company’s portfolio focus and improve growth and margin opportunities. Koch highlighted that the transaction is structured to maximize shareholder value by providing significant cash returns at close that can be reinvested for further value creation. Additionally, by retaining an equity interest in the merged entity, DuPont shareholders can participate in Arclin’s future growth prospects.

Arclin’s President and CEO, Bradley Bolduc, shared Koch’s excitement about the acquisition of Kevlar® and Nomex®, which he believes will drive transformative growth for the company. Bolduc emphasized the unique opportunity presented by the addition of these brands to Arclin’s portfolio, offering increased scale, global reach, and innovative application development capabilities. He expressed confidence in Arclin’s ability to leverage this acquisition to bring impactful solutions like Arclin Firepoint to the market, emphasizing the commitment to delivering quality products that protect critical assets.

The Aramids business is well-known for its invention and production of high-performance synthetic fibers such as Kevlar® and Nomex®, recognized globally for their quality, reliability, and performance in safeguarding people, equipment, and structures in high-risk scenarios. With approximately 1,900 employees across five manufacturing sites, the Aramids business reported net sales of $1.3 billion in 2024, solidifying its position as a leader in the industry.

It is important to note that the divestiture of the Aramids business will not impact DuPont’s intended separation of its electronics sector, Qnity, which remains on track for a spin-off on November 1, 2025. DuPont’s strategic decision to divest certain businesses aligns with its vision to streamline operations, enhance portfolio flexibility, and drive sustainable growth in key markets.

The transaction has been well-received by experts in the industry, with Centerview Partners and Goldman Sachs & Co. LLC providing financial advisory services for DuPont, and Skadden, Arps, Slate, Meagher & Flom LLP serving as legal counsel. Meanwhile, Piper Sandler & Company and Kirkland & Ellis LLP are advising TJC/Arclin on the transaction.

Overall, DuPont’s agreement to divest its Aramids business to Arclin represents a significant step in the company’s strategic transformation, allowing it to optimize its portfolio focus, improve financial performance, and drive long-term value for shareholders. The acquisition of Kevlar® and Nomex® by Arclin sets the stage for exciting growth opportunities, underscoring the commitment to innovation and excellence in the materials science industry.